The Growth Hormone Hypothesis - 2005 Revision

Growth hormone (GH) and insulin-like growth factor I (IGF-I) have been suggested to play a leading role in the development of diabetic retinopathy for more than three decades . At the time of writing, there is a substantial amount of experimental data supporting a role of GH and IGF-I in the development of diabetic retinopathy, whereas clinical trials have yielded variable results. However, both hormones, with IGF-I as the ringleader, remain under suspicion as pathogenic agents. This mini-review will discuss the current literature on the possible involvement of GH and IGF-I in the development of diabetic retinopathy. Hopefully, the reader will agree that although the indictment against GH and IGF-I has celebrated its 34th anniversary, it is still attractive from a scientific point of view.

[1]  J. Frystyk.  Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[2]  D. Dunger,et al.  Therapeutic applications of the insulin-like growth factors. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[3]  P. McGuire,et al.  Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition , 2003, Progress in Retinal and Eye Research.

[4]  T. Bek,et al.  The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[5]  T. Bek,et al.  Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. , 2003, Diabetes.

[6]  P. Sönksen,et al.  The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasis , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[7]  E. C. Stevens,et al.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. , 2002, Endocrine reviews.

[8]  G. Yancopoulos,et al.  Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. , 2002, The Journal of clinical investigation.

[9]  G. Lang,et al.  Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[10]  J. Spranger1,et al.  Systemic Levels Contribute Significantly to Increased Intraocular IGF-I, IGF-II and IFG-BP3 in Proliferative Diabetic Retinopathy , 2000 .

[11]  R. Cooper-DeHoff,et al.  The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. , 2000, Diabetes care.

[12]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[13]  G. Lang,et al.  Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[14]  H. Orskov,et al.  Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. , 1999, Kidney international.

[15]  H. Arnqvist,et al.  The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[16]  J. Frystyk,et al.  Circulating levels of free insulin‐like growth factors in obese subjects: the impact of Type 2 diabetes , 1999, Diabetes/metabolism research and reviews.

[17]  F. Cavagnini,et al.  Growth hormone in obesity , 1999, International Journal of Obesity.

[18]  P. Clauson,et al.  Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. , 1998, Scandinavian journal of clinical and laboratory investigation.

[19]  R. Tarnuzzer,et al.  Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[20]  D. Dunger,et al.  Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus , 1997, The Lancet.

[21]  J. Spranger,et al.  Growth Factor Alterations in Advanced Diabetic Retinopathy: A Possible Role of Blood Retina Barrier Breakdown , 1997, Diabetes.

[22]  Lois E. H. Smith,et al.  Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.

[23]  M. Boulton,et al.  Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management , 1997, The British journal of ophthalmology.

[24]  E. Schönau,et al.  Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac’s syndrome , 1997, The British journal of ophthalmology.

[25]  R. Young,et al.  Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus. , 1995, The Journal of clinical endocrinology and metabolism.

[26]  R. Klein,et al.  Does Insulin-Like Growth Factor I Predict Incidence and Progression of Diabetic Retinopathy? , 1995, Diabetes.

[27]  H. Freyberger,et al.  Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. , 1993, The Journal of clinical investigation.

[28]  W. Millard,et al.  Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization , 1993, Regulatory Peptides.

[29]  T. Schoen,et al.  Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. , 1993, Experimental eye research.

[30]  B. Vialettes,et al.  Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. , 1992, Diabete & metabolisme.

[31]  P. Chomczyński,et al.  Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Zinman,et al.  Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. , 1990, Clinical and investigative medicine. Medecine clinique et experimentale.

[33]  M. Larsen,et al.  Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. , 1990, Acta endocrinologica.

[34]  M. Grant,et al.  Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. , 1990, Current eye research.

[35]  R. Klein,et al.  Is Insulinlike Growth Factor I Associated With Diabetic Retinopathy? , 1990, Diabetes.

[36]  E. Kohner,et al.  Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. , 1989, Acta endocrinologica.

[37]  E. Kohner,et al.  Progression of Diabetic Retinopathy and Changes in Serum Insulin-Like Growth Factor I (IGF I) during Continuous Subcutaneous Insulin Infusion (CSII) , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[38]  Shingo Komine,et al.  Growth Hormone Responses to Growth-Hormone-Releasing Hormone and Thyrotropin-Releasing Hormone in Diabetic Patients With and Without Retinopathy , 1985, Diabetes.

[39]  E. Kohner,et al.  Growth Hormone Response to Hyperinsulinaemia in Insulin‐dependent Diabetics Comparison of Patients With and Without Retinopathy , 1984, Diabetic medicine : a journal of the British Diabetic Association.

[40]  E. Froesch,et al.  Insulin-like growth factors. Studies in diabetics with and without retinopathy. , 1983, The New England journal of medicine.

[41]  J. Schlienger,et al.  Growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics with or without severe microvascular lesions. , 1982, Diabete & metabolisme.

[42]  K. Lundbaek,et al.  Twenty-Four-Hour Serum Growth Hormone Levels in Maturity-Onset Diabetics , 1975, Diabetes.

[43]  K. Johansen,et al.  Diurnal Serum Growth Hormone Levels in Poorly and Well-controlled Juvenile Diabetics , 1971, Diabetes.

[44]  A. Rose.  Diabetes, diabetic angiopathy, and growth hormone. , 1970, Lancet.

[45]  E. Kohner,et al.  Serum Growth Hormone Levels and the Response of Diabetic Retinopathy to Pituitary Ablation* , 1969, British medical journal.

[46]  H. Ørskov,et al.  Wick Chromatography for Rapid and Reliable Immunoassay of Insulin, Glucagon and Growth Hormone , 1968, Nature.

[47]  M. Grant,et al.  Somatostatin analogues as drug therapies for retinopathies. , 2002, Drugs of today.

[48]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[49]  R. Beck,et al.  The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. , 2001, Ophthalmology.

[50]  R. Simó,et al.  Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. , 2000, Diabetes care.

[51]  L. Groop,et al.  Growth hormone response to the insulin tolerance and clonidine tests in type 1 diabetes. , 1999, Scandinavian journal of clinical and laboratory investigation.

[52]  F. V. van Kuijk,et al.  Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. , 1994, Current eye research.

[53]  D. Eckland,et al.  Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: A pilot study , 1991, Eye.

[54]  H. Olivecrona,et al.  Hypophysectomy in man; further experiences in severe diabetes mellitus. , 1955, British medical journal.